We would love to hear your thoughts about our site and services, please take our survey here.
So TheoremRx haven’t completed their fundraising and it may not be until the end of Q1. Surely this is not a good RNS?
An RNS is required for material announcements. “There may be a delay of a few days” is not a material announcement and therefore is not required. It is good that we haven’t had a “the deal fell over” RNS so far. Nevertheless, I do feel as nervous as everyone else as this drags into 2022.
News could drop at any time and we have no assurance that TheoremRx aren’t just stringing us along. Slightly concerned that there is still precisely zero literature on this company on the internet.
This board seems to have bipolar disorder. Chill out! There has been no backtracking. It’s in TheoremRx’s court. To say that Suzy didn’t need to give a timeframe is nonsense. She gave one and is trying to stick to it. What sort of idiot calls Suzy an amateur for doing exactly the right thing all the way throughout this? Muppet.
Only a half day of trading tomorrow then I think closed til 29th. 7am RNS from Val would be good so we have a good idea how the market is assessing the deal
Not just that Suzy would take a dim view… it’s also criminal to trade on insider information. I just don’t understand what pushed the price today.
Agree that the ups and downs are a bit of fun… most of my investments are in my nice boring pension plan, just like to play with my extra cash on the stock market… just nice to have more wins than losses!
I currently have covid and not looking like there will be much going on over Christmas for me, thus my increased interest in the boards right now!
Nothing obvious driving the price movements today, although it was on low volumes.
It’s not just Suzy that will be in the know on this though… presumably lawyers, brokers, etc all on the Insider List… and there’s always a risk someone will accidentally let something slip.
I’m definitely hopeful the moves were based on something positive, sold a bunch of other shares to increase my stake in Val today so I hope it’s more than a pump and dump as I have lost too much money elsewhere this month!
Perhaps I’ve misunderstood, but I didn’t take from the RNS that Valirx now has full control over VAL201… happy to be proved wrong! My understanding is that payment schedules have been changed (presumably so that Valirx only needs to pay CRT when it gets cash from TheoremRx) and there’s a greater level of flexibility in future sub-licensing deals (perhaps limited to deals with TheoremRx). At the end of the RNS it states that approval is required from CRT for future licensing activity.
I can’t see why this would be problematic, as CRT have an incentive to get VAL201 out in the world… but clearly Valirx still has obligations to CRT.
Do we have any idea what any payments to CRT will look like going forward? In particular would this materially reduce our net income stream expected under the sub-licensing arrangements?
Broker can’t give the institutional investors any more information than we already have. We are all excited but nervous about completion of the deal that is yet to come. Investing in AIM, we clearly have a big risk appetite. Risk goes down when you know cash flow is sorted for the medium term. In the new year I fully expect some positions being taken by low to medium risk-appetite institutions who are happy to invest knowing they won’t need to stump up any more cash in the mid term. If you have appetite for risk, now is surely the time to jump in, before Cenkos’ efforts come to fruition
Chill out guys. It’s someone with a view/interest
I’m with OB… if you’re planning to hold for the long run then the rahels of this world shouldn’t matter
Of course, a clever investor takes into account changes in circumstances when evaluating their investments…
I suppose my only concern is if we have been drip fed this piece of information because the TheoremRx deal is looking unlikely to complete in 2021. Hopefully not… and all indications are that it’s going to happen in the very near future!
Can’t see why not - the RNS is quite clear that this agreement with CRT enables the TheoremRx agreement to proceed. Everything lining up beautifully
There’s enough pressure to get this done that I would imagine it’s this side of New Year or not at all. There might be moving parts on the legal docs but I would imagine substantially agreed now. Once there’s a final meeting of the minds it’s very easy for the lawyers to confirm agreement then Suzy and TheoremRx to DocuSign the final agreement from home whenever. Focus on 31 December, that’s the key date!
Had a quick look at the financial statements just now… most of the debt seems to be floating rate, although there do seem to be some interest rate swaps which could effectively convert some of the interest to fixed. That said, it seems that there is indeed exposure to interest rate movements, and not only by reference to UK base rate
I suspect the Letter of Intent will have provided exclusivity to TheoremRx until 31 December. In which case, this could well go up to the wire (as it often does on deals) - no doubt TheoremRx would want to make the most of the time available to get themselves comfortable. Just need to be patient… might not be a Christmas gift, but hopefully one for New Year at least!
Definitely excited about this company. Fingers crossed on VAL201, slightly too nervous to put more cash in right now but sure I’ll end up regretting it.
Any idea what the additional opportunities will do to operating costs? I assume they will need to take more people on to fund the extra work, but it’s a pretty strong indication that the deal is in the bag to see that the pipeline is being actively expanded particularly given cash is (currently) tight
Do we know anything about the FCA perspective on all this? I see the comments in the docs that FCA hasn’t approved etc etc but do we have any idea how involved they have been in getting the scheme to where it is now? Presumably to an extent at least?
Any idea what drove share price on Friday? I really don’t understand why it went up when it had been flat/negative following the Suzy presentation
Valtree - what exactly is it you don’t believe in? The drugs or the management team?
The FCA has the Practice Statement Letter and will agree to it (or not) before the end of 2021. If they're on board, then surely it wouldn't make sense for them to then reject the Scheme or deny Amigo the ability to lend. I assume the court will go along with the FCA (it seemed happy to do so last time), and the customers would presumably go along with the committee.
So... is it reasonable for me to conclude that we are likely to have a very clear view of the future of the business before the start of 2022?